Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

SK bioscience wins patent lawsuit against Pfizer over pneumococcal vaccine in Korea: Gyeonggi-do, Republic of Korea Friday, May 23, 2025, 10:00 Hrs [IST] SK bioscience, a global i ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

The Global Nanomedicine Market is expected to witness a growth rate of 10-12% in the next five years. Ongoing research and ...

Thanks to generous support and partnership from Alexandria Real Estate Equities, Inc., Fred Hutch has a new, state-of-the-art ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer ... clinical research, as well as developing partnerships ...